Global Infliximab and Biosimilar Sales Market Report 2021

1 Infliximab and Biosimilar Market Overview

• 1.1 Infliximab and Biosimilar Product Scope
• 1.2 Infliximab and Biosimilar Segment by Type
  • 1.2.1 Global Infliximab and Biosimilar Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 Infliximab
  • 1.2.3 Infliximab-dyyb
  • 1.2.4 Infliximab-abda
• 1.3 Infliximab and Biosimilar Segment by Application
  • 1.3.1 Global Infliximab and Biosimilar Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 Crohn's Disease
  • 1.3.3 Pediatric Crohn's Disease
  • 1.3.4 Ulcerative Colitis
  • 1.3.5 Rheumatoid Arthritis
  • 1.3.6 Ankylosing Spondylitis
  • 1.3.7 Psoriatic Arthritis
  • 1.3.8 Plaque Psoriasis
• 1.4 Infliximab and Biosimilar Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global Infliximab and Biosimilar Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global Infliximab and Biosimilar Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global Infliximab and Biosimilar Price Trends (2016-2027)

2 Infliximab and Biosimilar Estimates and Forecasts by Region

• 2.1 Global Infliximab and Biosimilar Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global Infliximab and Biosimilar Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global Infliximab and Biosimilar Sales Market Share by Region (2016-2021)
  • 2.2.2 Global Infliximab and Biosimilar Revenue Market Share by Region (2016-2021)
• 2.3 Global Infliximab and Biosimilar Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global Infliximab and Biosimilar Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global Infliximab and Biosimilar Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America Infliximab and Biosimilar Estimates and Projections (2016-2027)
  • 2.4.2 Europe Infliximab and Biosimilar Estimates and Projections (2016-2027)
  • 2.4.3 China Infliximab and Biosimilar Estimates and Projections (2016-2027)
  • 2.4.4 Japan Infliximab and Biosimilar Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia Infliximab and Biosimilar Estimates and Projections (2016-2027)
  • 2.4.6 India Infliximab and Biosimilar Estimates and Projections (2016-2027)

3 Global Infliximab and Biosimilar Competition Landscape by Players

• 3.1 Global Top Infliximab and Biosimilar Players by Sales (2016-2021)
• 3.2 Global Top Infliximab and Biosimilar Players by Revenue (2016-2021)
• 3.3 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Infliximab and Biosimilar as of 2020)
• 3.4 Global Infliximab and Biosimilar Average Price by Company (2016-2021)
• 3.5 Manufacturers Infliximab and Biosimilar Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Infliximab and Biosimilar Market Size by Type

• 4.1 Global Infliximab and Biosimilar Historic Market Review by Type (2016-2021)
  • 4.1.1 Global Infliximab and Biosimilar Sales Market Share by Type (2016-2021)
  • 4.1.2 Global Infliximab and Biosimilar Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global Infliximab and Biosimilar Price by Type (2016-2021)
• 4.2 Global Infliximab and Biosimilar Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global Infliximab and Biosimilar Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Infliximab and Biosimilar Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global Infliximab and Biosimilar Price Forecast by Type (2022-2027)

5 Global Infliximab and Biosimilar Market Size by Application

• 5.1 Global Infliximab and Biosimilar Historic Market Review by Application (2016-2021)
  • 5.1.1 Global Infliximab and Biosimilar Sales Market Share by Application (2016-2021)
  • 5.1.2 Global Infliximab and Biosimilar Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global Infliximab and Biosimilar Price by Application (2016-2021)
• 5.2 Global Infliximab and Biosimilar Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global Infliximab and Biosimilar Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Infliximab and Biosimilar Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Infliximab and Biosimilar Price Forecast by Application (2022-2027)

6 North America Infliximab and Biosimilar Market Facts & Figures

• 6.1 North America Infliximab and Biosimilar Sales by Company
  • 6.1.1 North America Infliximab and Biosimilar Sales by Company (2016-2021)
  • 6.1.2 North America Infliximab and Biosimilar Revenue by Company (2016-2021)
• 6.2 North America Infliximab and Biosimilar Sales Breakdown by Type
  • 6.2.1 North America Infliximab and Biosimilar Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America Infliximab and Biosimilar Sales Breakdown by Type (2022-2027)
• 6.3 North America Infliximab and Biosimilar Sales Breakdown by Application
  • 6.3.1 North America Infliximab and Biosimilar Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America Infliximab and Biosimilar Sales Breakdown by Application (2022-2027)

7 Europe Infliximab and Biosimilar Market Facts & Figures

• 7.1 Europe Infliximab and Biosimilar Sales by Company
  • 7.1.1 Europe Infliximab and Biosimilar Sales by Company (2016-2021)
  • 7.1.2 Europe Infliximab and Biosimilar Revenue by Company (2016-2021)
• 7.2 Europe Infliximab and Biosimilar Sales Breakdown by Type
  • 7.2.1 Europe Infliximab and Biosimilar Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe Infliximab and Biosimilar Sales Breakdown by Type (2022-2027)
• 7.3 Europe Infliximab and Biosimilar Sales Breakdown by Application
  • 7.3.1 Europe 114 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 114 Sales Breakdown by Application (2022-2027)

8 China Infliximab and Biosimilar Market Facts & Figures

• 8.1 China Infliximab and Biosimilar Sales by Company
  • 8.1.1 China Infliximab and Biosimilar Sales by Company (2016-2021)
  • 8.1.2 China Infliximab and Biosimilar Revenue by Company (2016-2021)
• 8.2 China Infliximab and Biosimilar Sales Breakdown by Type
  • 8.2.1 China Infliximab and Biosimilar Sales Breakdown by Type (2016-2021)
  • 8.2.2 China Infliximab and Biosimilar Sales Breakdown by Type (2022-2027)
• 8.3 China Infliximab and Biosimilar Sales Breakdown by Application
  • 8.3.1 China 134 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 134 Sales Breakdown by Application (2022-2027)

9 Japan Infliximab and Biosimilar Market Facts & Figures

• 9.1 Japan Infliximab and Biosimilar Sales by Company
  • 9.1.1 Japan Infliximab and Biosimilar Sales by Company (2016-2021)
  • 9.1.2 Japan Infliximab and Biosimilar Revenue by Company (2016-2021)
• 9.2 Japan Infliximab and Biosimilar Sales Breakdown by Type
  • 9.2.1 Japan Infliximab and Biosimilar Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan Infliximab and Biosimilar Sales Breakdown by Type (2022-2027)
• 9.3 Japan Infliximab and Biosimilar Sales Breakdown by Application
  • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Infliximab and Biosimilar Market Facts & Figures

• 10.1 Southeast Asia Infliximab and Biosimilar Sales by Company
  • 10.1.1 Southeast Asia Infliximab and Biosimilar Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia Infliximab and Biosimilar Revenue by Company (2016-2021)
• 10.2 Southeast Asia Infliximab and Biosimilar Sales Breakdown by Type
  • 10.2.1 Southeast Asia Infliximab and Biosimilar Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia Infliximab and Biosimilar Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia Infliximab and Biosimilar Sales Breakdown by Application
  • 10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India Infliximab and Biosimilar Market Facts & Figures

• 11.1 India Infliximab and Biosimilar Sales by Company
  • 11.1.1 India Infliximab and Biosimilar Sales by Company (2016-2021)
  • 11.1.2 India Infliximab and Biosimilar Revenue by Company (2016-2021)
• 11.2 India Infliximab and Biosimilar Sales Breakdown by Type
  • 11.2.1 India Infliximab and Biosimilar Sales Breakdown by Type (2016-2021)
  • 11.2.2 India Infliximab and Biosimilar Sales Breakdown by Type (2022-2027)
• 11.3 India Infliximab and Biosimilar Sales Breakdown by Application
  • 11.3.1 India Infliximab and Biosimilar Sales Breakdown by Application (2016-2021)
  • 11.3.2 India Infliximab and Biosimilar Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Infliximab and Biosimilar Business

• 12.1 Janssen Biotech
  • 12.1.1 Janssen Biotech Corporation Information
  • 12.1.2 Janssen Biotech Business Overview
  • 12.1.3 Janssen Biotech Infliximab and Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Janssen Biotech Infliximab and Biosimilar Products Offered
  • 12.1.5 Janssen Biotech Recent Development
• 12.2 Merck and Co.
  • 12.2.1 Merck and Co. Corporation Information
  • 12.2.2 Merck and Co. Business Overview
  • 12.2.3 Merck and Co. Infliximab and Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 Merck and Co. Infliximab and Biosimilar Products Offered
  • 12.2.5 Merck and Co. Recent Development
• 12.3 Pfizer
  • 12.3.1 Pfizer Corporation Information
  • 12.3.2 Pfizer Business Overview
  • 12.3.3 Pfizer Infliximab and Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 Pfizer Infliximab and Biosimilar Products Offered
  • 12.3.5 Pfizer Recent Development

...

13 Infliximab and Biosimilar Manufacturing Cost Analysis

• 13.1 Infliximab and Biosimilar Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of Infliximab and Biosimilar
• 13.4 Infliximab and Biosimilar Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 Infliximab and Biosimilar Distributors List
• 14.3 Infliximab and Biosimilar Customers

15 Market Dynamics

• 15.1 Infliximab and Biosimilar Market Trends
• 15.2 Infliximab and Biosimilar Drivers
• 15.3 Infliximab and Biosimilar Market Challenges
• 15.4 Infliximab and Biosimilar Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List